Liquidia shares have surged 43.9% since an October upgrade, as Zacks highlights stock wins and portfolio results despite a volatile market.
AWH Capital L.P. bought a new position in shares of Liquidia Corporation (NASDAQ: LQDA) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 69,500 shares of the company's stock, valued at approximately $866,000. Liquidia comprises 1.0% of
The consensus price target hints at a 51.2% upside potential for Liquidia Corporation (LQDA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Liquidia Corporation ( LQDA ) Jefferies London Healthcare Conference 2025 November 18, 2025 8:00 AM EST Company Participants Roger Jeffs - CEO & Director Michael Kaseta - COO & CFO Conference Call Participants Amy Li - Jefferies LLC, Research Division Presentation Amy Li Jefferies LLC, Research Division Hi, everyone, thanks so much for attending the Liquidia fireside chat. Day 2 of the conference, the weather in London is getting a little chilly, but it's good for staying awake.
California-based TCG Crossover Management added 1.7 million shares of Liquidia for an estimated $38.9 million in the third quarter. The position represented 1.9% of reported assets at quarter-end.
The consensus price target hints at a 62.3% upside potential for Liquidia Corporation (LQDA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Y Intercept Hong Kong Ltd acquired a new stake in shares of Liquidia Corporation (NASDAQ: LQDA) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 62,235 shares of the company's stock, valued at approximately $775,000. Y Intercept Hong Kong Ltd owned about 0.07%
Liquidia Corporation has just posted strong Q3 results after a recent FDA approval, and the commercial launch of YUTREPIA is showing solid early sales traction. The Q3 earnings beat has triggered numerous upward price target revisions for LQDA stock from analyst firms. Liquidia has a solid balance sheet and is well on its way to consistent profitability.
Liquidia Corporation ( LQDA ) Q3 2025 Earnings Call November 3, 2025 8:30 AM EST Company Participants Jason Adair - Chief Business Officer Roger Jeffs - CEO & Director Michael Kaseta - COO & CFO Scott Moomaw - Chief Commercial Officer Rajeev Saggar - Chief Medical Officer Russell Schundler - General Counsel & Corporate Secretary Conference Call Participants Amy Li - Jefferies LLC, Research Division Cory Jubinville - LifeSci Capital, LLC, Research Division Julian Harrison - BTIG, LLC, Research Division Ryan Deschner - Raymond James & Associates, Inc., Research Division Serge Belanger - Needham & Company, LLC, Research Division Andrew Fein - H.C. Wainwright & Co, LLC, Research Division Benjamin Burnett - Wells Fargo Securities, LLC, Research Division Jason Gerberry - BofA Securities, Research Division Presentation Operator Good morning, and welcome to the Liquidia Corporation Third Quarter 2025 Financial Results and Corporate Update Conference Call.
MORRISVILLE, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today that members of the company's executive leadership team will be providing updates on the company's business during fireside chats at the following two investor conferences in November:
